undamentalytics Newsletter
Sign in

Gyre Therapeutics, Inc. (GYRE) stock

Add to watchlist

Add holding +

NASDAQ: GYRE Nasdaq Pharmaceuticals Next results ~November 5, 2026

Gyre Therapeutics, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Gyre Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 18 sales by directors and officers, last 12 monthsInsider trades
  • Funds42 adding, 16 cuttingOf 5 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Gyre Therapeutics files

Where Gyre Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $119m, up 13.5% on a year earlier, slower than the 19.2% growth a quarter earlier. Free-cash-flow margin rose to -5.1% from -9.2% a year earlier. Operating margin narrowed to -14.0% from 4.7%. The diluted share count is up 4.5% on a year earlier, which dilutes existing holders. It passes 2 of our 2 financial-health checks.

Our model value for Gyre Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Gyre Therapeutics, Inc.'s trailing-twelve-month revenue grew 13.5% year on year, with a free-cash-flow margin of -5.1%.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 13.5% (-5.7pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 6 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 5.7 points lower than a quarter earlier.
  • Loss-making. Operating margin is -14.0%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 18.7 points on a year ago.
  • Burning cash. Free cash flow was -5.1% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 4.5% in a year.

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
-$0.12 against an average estimate of -$0.06: missed by 111.8%
Revenue
$29m, down 2.1% on a year earlier
Share reaction
+5.0% in the first session after the results on August 7, 2026, against +0.6% for the S&P 500
Guidance given
revenue guidance $100.5m to $111m (Full year 2026)
Next report
November 5, 2026

Gyre Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.7%
  • 1 week-22.1%
  • 1 month-33.5%
  • This year-33.0%
  • 1 year-39.0%
  • 5 years-41.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$119M
Operating margin
-14.0%
Net margin
-23.6%
EPS (TTM, diluted)
$-0.27

Growth

Revenue growth
+13.5%
Change in growth rate
−5.7 pts
Share count change
+4.5%

Cash

Free cash flow (TTM)
-$6.1M
FCF margin
-5.1%
Stock pay % of revenue
8.5%

Earnings

Last results
August 7, 2026
Next results (est.)
November 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Announcement
  3. Announcement
  4. Results
  5. Guidance
  6. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Gyre Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Gyre Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.15 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$2.5 ~$2.0–$3.2 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Gyre Therapeutics, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20172018202020212022202320242025Now
Share price$33.30$19.26$15.40$2.22$4.92$25.69$12.10$7.06$4.73
Market value$238m$451m$617m$142m$778m$1.7bn$1.2bn$728m$489m
+ Net debt (− = net cash)−$9m−$31m−$30m−$44m−$25m−$34m−$12m−$49m−$43m
Enterprise value$229m$420m$587m$98m$753m$1.7bn$1.2bn$679m$446m
Multiples
Price / sales n/mn/m29.4x19.4x7.6x14.9x11.7x6.2x4.1x
Price / earnings ————180.3x—69.2x73.7x—
Price / free cash flow ————136.6x97.3x———
EV / EBITDA ————73.1x—69.2x48.6x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard Gyre Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -42.6% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -167.2%; its worst year was -7891.7%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 7 years, at a median -79.9% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 313.6% over five years; stock-based pay has been a median 12.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $28m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.40 −2100% $110m −6%
Next −$0.23 +41% $140m +28%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +37.9% on 90 days ago. In the last 30 days, 1 analyst raised Gyre Therapeutics, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Gyre Therapeutics, Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.29 Current fiscal year, 60 days ago: −$0.29 Current fiscal year, 30 days ago: −$0.29 Current fiscal year, 7 days ago: −$0.29 Current fiscal year, Now: −$0.40 −$0.40 Next fiscal year, 90 days ago: −$0.12 Next fiscal year, 60 days ago: −$0.12 Next fiscal year, 30 days ago: −$0.12 Next fiscal year, 7 days ago: −$0.12 Next fiscal year, Now: −$0.23 −$0.23

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.29−$0.12
60 days ago −$0.29−$0.12
30 days ago −$0.29−$0.12
7 days ago −$0.29−$0.12
Now −$0.40−$0.23

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.06 −$0.12 −111.8%
Mar 2026 −$0.07 −$0.10 −36.4%
Dec 2025 $0.01 $0.05 +368.0%
Sept 2025 −$0.02 $0.03 +250.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 7, 2026
  • revenue guidance Full year 2026 $101m to $111m Maintained
    “Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202633

Counts of recommendations published by analysts covering Gyre Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.5%
of tradable shares
Days to cover
9.81
at average volume
Short interest, 1 month
+11%
to October 15, 2026
Held by institutions
8%
of shares
Held by insiders
74.4%
of shares
Employees
625
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −39.0%

$7.75 on October 31, 2025 to $4.73

ThenNowEffect
Revenue (last 12 months) $105m $119m +13.5%
P/S multiple 7.3x 4.1x −43.8%
Share count 99m 103m −4.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
GYRE−86%+122%+422%−53%−42%−33%
Industry peers (median)−18%−52%−14%−2%+9%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
GYRE25%58%58%33%33%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
GYRE−87%−64%−52%−65%−50%−48%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 99% from November 2, 2015 to May 13, 2022. Getting back needed a 16483% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.56 – $8.76
From 52-week high
−46.0%
vs 50-day average
−29.3%
vs 200-day average
−32.2%
Volatility (1 year)
64%
Beta vs S&P 500
1.75

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±9.4%
After a week
6 up, 6 down
typical move ±11.6%
After a month
5 up, 7 down
typical move ±17.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 7, 2026 +5.0% +0.6% +4.4% +12.0%
May 7, 2026 −7.1% +0.5% −12.9% −24.8%
March 12, 2026 −9.2% −2.1% −18.4% −7.7%
November 7, 2025 +7.9% +1.7% +8.9% +9.5%
August 11, 2025 +5.1% +0.9% +9.2% +13.6%
May 9, 2025 +14.2% +3.2% +19.7% −5.1%
March 17, 2025 −29.2% −0.3% −23.9% −30.6%
February 18, 2025 +1.3% +0.5% −4.5% −14.2%
November 13, 2024 −13.6% −0.6% −19.4% −39.8%
August 13, 2024 −6.5% +2.0% +9.9% +28.7%
May 9, 2024 −5.5% +0.7% −2.5% −28.5%
March 26, 2024 +8.3% +0.7% +6.1% +0.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Gyre Therapeutics, Inc.
$0 $50M $100M $150M FY22 Q1 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY22 Q1: $6.7M Revenue (TTM), FY23 Q4: $113.5M Revenue (TTM), FY24 Q1: $115.7M Revenue (TTM), FY24 Q2: $111.6M Revenue (TTM), FY24 Q3: $105M Revenue (TTM), FY24 Q4: $105.8M Revenue (TTM), FY25 Q1: $100.6M Revenue (TTM), FY25 Q2: $105.2M Revenue (TTM), FY25 Q3: $110.2M Revenue (TTM), FY25 Q4: $119.6M Revenue (TTM), FY26 Q1: $120M Revenue (TTM), FY26 Q2: $119.4M $119.4M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY22 Q1 $6.7M
FY23 Q4 $113.5M
FY24 Q1 $115.7M
FY24 Q2 $111.6M
FY24 Q3 $105M
FY24 Q4 $105.8M
FY25 Q1 $100.6M
FY25 Q2 $105.2M
FY25 Q3 $110.2M
FY25 Q4 $119.6M
FY26 Q1 $120M
FY26 Q2 $119.4M
Revenue growth, TTM YoY Gyre Therapeutics, Inc.
-100% -50% 0% 50% FY14 Q4 FY21 Q4 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY14 Q4: -92.4% Revenue growth, TTM YoY, FY15 Q1: 37.8% Revenue growth, TTM YoY, FY15 Q2: -1.9% Revenue growth, TTM YoY, FY21 Q4: -65.0% Revenue growth, TTM YoY, FY22 Q1: 10.2% Revenue growth, TTM YoY, FY24 Q4: -6.8% Revenue growth, TTM YoY, FY25 Q1: -13.0% Revenue growth, TTM YoY, FY25 Q2: -5.8% Revenue growth, TTM YoY, FY25 Q3: 4.9% Revenue growth, TTM YoY, FY25 Q4: 13.0% Revenue growth, TTM YoY, FY26 Q1: 19.2% Revenue growth, TTM YoY, FY26 Q2: 13.5% 13.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY14 Q4 -92.4%
FY15 Q1 37.8%
FY15 Q2 -1.9%
FY21 Q4 -65.0%
FY22 Q1 10.2%
FY24 Q4 -6.8%
FY25 Q1 -13.0%
FY25 Q2 -5.8%
FY25 Q3 4.9%
FY25 Q4 13.0%
FY26 Q1 19.2%
FY26 Q2 13.5%
Operating margin (TTM) Gyre Therapeutics, Inc.
-1500% -1000% -500% 0% 500% FY22 Q1 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY22 Q1: -1202.7% Operating margin (TTM), FY23 Q4: -59.3% Operating margin (TTM), FY24 Q1: -56.9% Operating margin (TTM), FY24 Q2: -60.6% Operating margin (TTM), FY24 Q3: -72.5% Operating margin (TTM), FY24 Q4: 15.3% Operating margin (TTM), FY25 Q1: 10.3% Operating margin (TTM), FY25 Q2: 4.7% Operating margin (TTM), FY25 Q3: 6.9% Operating margin (TTM), FY25 Q4: 5.9% Operating margin (TTM), FY26 Q1: -3.8% Operating margin (TTM), FY26 Q2: -14.0% -14.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY22 Q1 -1202.7%
FY23 Q4 -59.3%
FY24 Q1 -56.9%
FY24 Q2 -60.6%
FY24 Q3 -72.5%
FY24 Q4 15.3%
FY25 Q1 10.3%
FY25 Q2 4.7%
FY25 Q3 6.9%
FY25 Q4 5.9%
FY26 Q1 -3.8%
FY26 Q2 -14.0%
FCF margin (TTM) Gyre Therapeutics, Inc.
-600000% -400000% -200000% 0% 200000% FY18 Q4 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY18 Q4: -482150.0% FCF margin (TTM), FY23 Q4: 15.3% FCF margin (TTM), FY24 Q1: 9.8% FCF margin (TTM), FY24 Q2: 2.1% FCF margin (TTM), FY24 Q3: -2.1% FCF margin (TTM), FY24 Q4: -5.6% FCF margin (TTM), FY25 Q1: -8.8% FCF margin (TTM), FY25 Q2: -9.2% FCF margin (TTM), FY25 Q3: 2.6% FCF margin (TTM), FY25 Q4: -0.2% FCF margin (TTM), FY26 Q1: 2.6% FCF margin (TTM), FY26 Q2: -5.1% -5.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY18 Q4 -482150.0%
FY23 Q4 15.3%
FY24 Q1 9.8%
FY24 Q2 2.1%
FY24 Q3 -2.1%
FY24 Q4 -5.6%
FY25 Q1 -8.8%
FY25 Q2 -9.2%
FY25 Q3 2.6%
FY25 Q4 -0.2%
FY26 Q1 2.6%
FY26 Q2 -5.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Gyre Therapeutics took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $117M
  2. Other income $2.9M · 2.5%
  3. Cost of revenue $5.4M · 4.6%
  4. Gross profit $111M · 95.4%
  5. Research and development $13.7M · 11.7%
  6. Selling, general and admin $86M · 73.7%
  7. Operating income $11.5M · 9.9%
  8. Income tax $4.6M · 3.9%
  9. Net income $9.9M · 8.5%

Shares of revenue. Source: Gyre Therapeutics's 10-K for FY2025, as filed with the SEC. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2017 Dec 2017 2018 Dec 2018 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 25 86 98 58 4 0 1 0 21 7 102 113 106 117 119
Gross profit — — — — — — — — — — 97 109 102 111 113
EBITDA −38 15 −7 −6 −9 −7 −22 −34 −57 −88 10 −66 18 14 −14
Operating income −40 13 −10 −8 −10 −8 −22 −34 −57 −88 9 −67 16 11 −17
Net income −39 11 −9 −7 −10 −7 −22 −30 −56 −88 4 −85 18 10 −28
Diluted EPS −$0.74 $0.17 −$1.94 −$0.10 −$13.07 −$8.62 −$3.57 −$1.28 −$1.40 −$1.37 $0.01 −$1.41 $0.05 $0.02 −$0.27
Growth (year on year)
Revenue — +242.0% +13.9% −40.7% −93.7% −92.4% +270.2% −99.4% +>999% −65.0% +>999% +10.9% −6.8% +10.2% +13.5%
EBITDA — — −148.1% — — — — — — — — −742.9% — −21.1% −294.7%
Operating income — — −174.3% — — — — — — — — −830.5% — −28.9% −438.2%
Net income — — −178.3% — — — — — — — — <−999% — −44.8% −558.6%
Diluted EPS — — <−999% — — — — — — — — <−999% — −60.0% −538.7%
Margins
Gross margin — — — — — — — — — — 95.3% 95.9% 96.3% 95.4% 94.3%
EBITDA margin −153.6% 17.6% −7.4% −10.2% −252.0% <−999% <−999% <−999% −273.2% <−999% 10.1% −58.3% 16.7% 12.0% −11.7%
Operating margin −160.9% 15.3% −10.0% −14.1% −278.9% <−999% <−999% <−999% −273.9% <−999% 9.0% −59.3% 15.3% 9.9% −14.0%
Net margin −157.2% 12.7% −8.7% −12.1% −274.6% <−999% <−999% <−999% −268.5% <−999% 4.2% −75.3% 16.9% 8.5% −23.6%
Free-cash-flow margin −97.6% 157.5% −87.2% −111.6% <−999% <−999% <−999% <−999% — <−999% 5.6% 15.3% −5.6% −0.2% −5.1%
Cash flow
Cash from operations −24 138 −84 −64 −41 −6 −20 −29 −55 −84 11 26 −4 1 −5
Capital spending 0 3 1 0 0 0 0 0 — 1 5 9 2 1 1
Free cash flow −24 135 −85 −65 −41 −6 −20 −29 — −85 6 17 −6 −0 −6
Stock-based pay 2 5 9 8 0 0 1 3 4 3 13 7 1 7 10
Free cash flow after stock pay −27 130 −94 −72 −41 −7 −21 −32 — −88 −8 10 −7 −7 −16
Balance sheet
Cash 84 166 107 3 3 2 14 31 30 44 25 34 12 49 43
Total debt 0 3 3 2 1 0 5 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −84 −163 −104 −1 −2 −2 −9 −31 −30 −44 −25 −34 −12 −49 −43
Diluted shares 54m 63m 66m 70m — — 7m 23m 40m 64m 158m 66m 102m 103m 103m
Returned to shareholders
Dividends — — — — — — — — — — 45 — — — —
Total returned — — — — — — — — — — 45 — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $199m
Short-term assets $122mLonger-term assets $77m
What it owes, and who funded it · $142m
Short-term liabilities $29mLonger-term liabilities $6mShareholders' equity $108m
  • Short-term assets cover short-term liabilities $122m of assets due within a year against $29m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $122m short-term assets against $6m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Gyre Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+4.5%
year over year
R&D spending
18.6%
of revenue
Days sales outstanding
85 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated GYRE NAGE ETON ZVRA NAII HRTX Median
Revenue, last 12 months $119m $129m $106m $136m $143m $151m $254m
Revenue growth, last 12 months 13.5% 11.0% 81.5% 119.4% 9.7% 1.0% 10.0%
Revenue growth, 3-year average 153.4% 16.8% 53.8% 101.9% −2.6% 8.6% 5.9%
Revenue growth, latest quarter −2.1% −4.3% 98.6% 53.3% 1.9% 1.3% 6.4%
Gross margin 94.3% 64.2% 57.9% 89.3% 6.3% 70.1% 63.8%
Operating margin −14.0% 8.2% 15.4% 60.5% −13.2% −7.2% −5.9%
Operating margin, 3-year average −23.3% 6.6% −2.0% −149.1% −9.1% −13.5% −8.5%
Net margin −23.6% 12.4% 12.0% 42.8% −14.5% −22.5% −7.4%
Cash from operations / revenue −4.1% 4.6% 14.3% 24.5% −6.3% −7.7% 9.4%
Free-cash-flow margin −5.1% 4.2% 14.0% 24.0% −8.9% −8.0% 8.1%
Free-cash-flow margin, 3-year average −4.1% 7.4% 11.7% −96.2% −3.7% −47.0% 6.6%
Stock pay / revenue 8.5% 5.4% 4.9% 9.6% 0.4% 7.4% 3.7%
Change in share count 4.5% 2.5% 29.1% 13.4% 1.4% 5.9% 2.0%

Median of all 76 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$57.1M
Institutions reporting
59
Shares held vs prior quarter
▲ 154.3%
Positions opened / closed
12 / 7

Top buyers and sellers, Q2 2026: 42 institutions bought and 16 sold ; the biggest buyer was Hsg Holding Ltd (+3.8M shares) and the biggest seller Vanguard Capital Management LLC (−107K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Hsg Holding Ltd $24.7M 3.8M 43.3% New
Blackrock, Inc. $6.6M 994K 11.5% ▲ 31.0%
Octagon Capital Advisors LP $6.3M 954K 11.0% New
Vanguard Capital Management LLC $5.8M 877K 10.1% ▼ 10.9%
Geode Capital Management, LLC $3.5M 533K 6.2% ▲ 23.5%
State Street Corp $1.6M 245K 2.8% ▲ 13.4%
Charles Schwab Investment Management Inc $1.2M 184K 2.1% ▲ 11.5%
Northern Trust Corp $1.1M 170K 2.0% ▲ 26.7%
Sbi Securities Co., Ltd. $1.1M 167K 1.9% ▼ 2.4%
Vanguard Fiduciary Trust Co $995,571 151K 1.7% ▲ 9.7%
Vanguard Portfolio Management LLC $816,850 124K 1.4% ▲ 77.5%
Goldman Sachs Group Inc $568,289 86K 1.0% ▲ 17.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Gyre Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $952,874 18 trades by 2 insiders · 9% under pre-set plans
Net ▼ $952,874 net selling
Insider Date Trade Shares Price Value
Ye Weiguo Chief Operating Officer June 18, 2026 Sell 3,000 $6.35 $19,050
Ye Weiguo Chief Operating Officer June 11, 2026 Sell 2,800 $6.17 $17,276
Ye Weiguo Chief Operating Officer June 10, 2026 Sell 6,418 $6.21 $39,856
Ye Weiguo Chief Operating Officer June 10, 2026 Sell 5,000 $6.24 $31,200
Ye Weiguo Chief Operating Officer June 9, 2026 Sell 14,500 $6.14 $89,030
Ye Weiguo Chief Operating Officer June 9, 2026 Sell 3,000 $6.15 $18,450
Ye Weiguo Chief Operating Officer June 5, 2026 Sell 15,401 $6.40 $98,566
Ye Weiguo Chief Operating Officer June 4, 2026 Sell 19,575 $6.13 $119,995
Ye Weiguo Chief Operating Officer May 26, 2026 Sell 4,000 $6.10 $24,400
Ye Weiguo Chief Operating Officer May 22, 2026 Sell 3,500 $6.08 $21,280
Ye Weiguo Chief Operating Officer May 21, 2026 Sell 12,820 $6.15 $78,843
Ye Weiguo Chief Operating Officer May 20, 2026 Sell 9,400 $6.15 $57,810

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 6, 2026 estimated from the company's past filing pattern, not announced

  • August 7, 2026
  • May 7, 2026
  • March 12, 2026
  • November 7, 2025
  • August 11, 2025
  • May 9, 2025

Recent SEC filings

Data status

When each part of this page on Gyre Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Gyre Therapeutics, Inc. in brief

What does Gyre Therapeutics, Inc. do?
Gyre Therapeutics, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Gyre Therapeutics, Inc.'s stock ticker?
Gyre Therapeutics, Inc. trades under the ticker GYRE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Gyre Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Gyre Therapeutics, Inc. reported revenue of $119M, 13.5% higher than a year earlier, according to its SEC filings.
What is Gyre Therapeutics, Inc.'s free cash flow?
Gyre Therapeutics, Inc.'s free-cash-flow margin is -5.1% of revenue over the trailing twelve months.
Who are Gyre Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Hsg Holding Ltd, Blackrock, Inc. and Octagon Capital Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Gyre Therapeutics, Inc.'s market cap?
On November 2, 2026, Gyre Therapeutics, Inc.'s market capitalisation was about $489M and net debt of -$43.3M. Market figures come from third-party market data and may be delayed.
Who are Gyre Therapeutics, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Gyre Therapeutics, Inc. are Niagen Bioscience, Inc., Eton Pharmaceuticals, Inc., Zevra Therapeutics, Inc., Natural Alternatives International Inc and Heron Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Gyre Therapeutics, Inc.'s.
Are insiders buying or selling Gyre Therapeutics, Inc. stock?
Over the last 12 months, Gyre Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 18 sales on Form 4. The insider trading page charts every trade.
When is Gyre Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Gyre Therapeutics, Inc. announces its own schedule.